PriceTargets.com logo

WuXi Biologics (Cayman) - WXXWY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$12.55 As of 11/29/2022 01:00 AM ET
▲ +0.17 (1.37%)

This chart shows the closing price for WXXWY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New WuXi Biologics (Cayman) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WXXWY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WXXWY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for WuXi Biologics (Cayman) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $12.55.

This chart shows the closing price for WXXWY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in WuXi Biologics (Cayman). This rating has held steady since August 2022, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/26/2022Sanford C. BernsteinInitiated CoverageOutperform
8/8/2021The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
10/11/2020The Goldman Sachs GroupInitiated CoverageBuy
5/28/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy
1/4/2018JPMorgan Chase & Co.Initiated CoverageOverweight
(Data available from 11/30/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/4/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
WuXi Biologics (Cayman) logo
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Read More

Today's Range

Now: $12.55
Low: $12.38
High: $12.67

50 Day Range

MA: $11.90
Low: $8.95
High: $13.85

52 Week Range

Now: $12.55
Low: $8.70
High: $27.70

Volume

450,095 shs

Average Volume

272,434 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of WuXi Biologics (Cayman)?

The following Wall Street analysts have issued stock ratings on WuXi Biologics (Cayman) in the last year: Sanford C. Bernstein.
View the latest analyst ratings for WXXWY.

What is the current price target for WuXi Biologics (Cayman)?

0 Wall Street analysts have set twelve-month price targets for WuXi Biologics (Cayman) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for WuXi Biologics (Cayman) in the next year.
View the latest price targets for WXXWY.

What is the current consensus analyst rating for WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe WXXWY will outperform the market and that investors should add to their positions of WuXi Biologics (Cayman).
View the latest ratings for WXXWY.

What other companies compete with WuXi Biologics (Cayman)?

Other companies that are similar to WuXi Biologics (Cayman) include 3SBio, Abattis Bioceuticals, Abcam, Adocia and Ainos. Learn More about companies similar to WuXi Biologics (Cayman).